Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study

Neuroendocrinology Letters

Volumn 30, Issue 2, 2009, Pages 256-261

  Hrdlicka, Michal ^a   Zedkova, Iveta ^a   Blatny, Marek ^b   Urbanek, Tomas ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b PSYCHOLOGICKÝ ÚSTAV AV CR   (Czech Republic)

Author keywords

Adolescence; Antipsychotics; Schizophrenia; Weight gain

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

ADOLESCENT; ARTICLE; CONTROLLED STUDY; FOLLOW UP; HUMAN; ONSET AGE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

EID: 70349336075     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Akkaya C, Sarandol A, Cangur S, Kirli S (2007). Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting. Hum Psychopharmacol Clin Exp. 22: 515-528.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 156: 1688-1696. (Pubitemid 29517559)
3. Armenteros JL, Davies M (2006). Antipsychotics in early onset schizophrenia: systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 15: 141-148.
4. Blin O, Micallef J (2001). Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry. 62 (Suppl 7): 11-21. (Pubitemid 32402181)
5. Connor DF, Fletcher KE, Wood JS (2001). Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry. 62: 967-974.
6. Correll CU (2008). Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry. 69 (Suppl 4): 26-36.
7. Ebbeling CB, Pawlak DB, Ludwig DS (2002). Childhood obesity: public-health crisis, common sense cure. Lancet. 360: 473-482.
8. Findling RL, Steiner H, Weller EB (2005). Use of antipsychotics in children and adolescents. J Clin Psychiatry. 66 (Suppl 7): 29-40.
9. Fleischhacker WW, Hummer M (1997). Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs. 53: 915-929.
10. Fleischhaker C, Heiser P, Hennighausen K, Herpertz B, Holtkamp K, Mehler-Wex C, et al (2007). Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm. 114: 273-280. (Pubitemid 46147166)
11. Geddes J, Freemantle N, Harrison P, Bebbington P (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 321: 1371-1376.
12. Gerlach J, Peacock L (1995) New antipsychotics: the present status. Int Clin Psychopharmacol. 10 (Suppl.3): 39-48.
13. Henderson DC (2007). Weight gain with atypical antipsychotics: evidence and insights. J Clin Psychiatry. 68 (Suppl 12): 18-26. (Pubitemid 350021619)
14. Hrdlicka M, Dudova I (2007). Risperidone in adolescent schizophrenic psychoses: a retrospective study. Int J Psychiatry Clin Pract. 11: 273-278. (Pubitemid 350135861)
15. Jones B, Basson BR, Walker DJ, Crawford AMK, Kinon BJ (2001). Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry. 62 (Suppl 2): 41-44. (Pubitemid 32154141)
16. Kasper S, Rosillon D, Duchesne I (2001). Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol. 16: 179-187. (Pubitemid 32612515)
17. Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, et al (2008). Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 34: 60-71. (Pubitemid 350262286)
18. Mohr P (2007). Quality of life in the long-term treatment and the role of second-generation antipsychotics. Neuroendocrinol Lett. 28 (Suppl 1): 117-133. (Pubitemid 46534377)
19. Newcomer JW, Haupt DW (2006). The metabolic effects of antipsychotic medications. Can J Psychiatry. 51: 480-491.
20. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, et al (2002). Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolescent Psychiatry. 41: 337-343. (Pubitemid 38338156)
21. Sadock BJ, Sadock VA, editors (2005). Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Philadelphia: Lippincott Williams & Wilkins.
22. Sen Y, Aygun D, Yilmaz E, Ayar A (2008). Children and adolescents with obesity and the metabolic syndrome have high circulating Cortisol levels. Neuroendocrinol Lett. 29: 141-145.
23. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, et al (2006). Childhood-onset schizophrenia, a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 63: 721-730.
24. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA (2004). A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 29: 133-145. (Pubitemid 38068023)
25. Stahl SM (1999). Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry. 60 (Suppl 10): 31-41.
26. Taylor DM, McAskill R (2000). Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand. 101: 416-432. (Pubitemid 30365564)
27. Ucok A, Gaebel W (2008). Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 7: 58-62. (Pubitemid 351338194)
28. Virk S, Schwartz TL, Jindal S, Nihalani N, Jones N (2004). Psychiatric medication induced obesity: an aetiologic review. Obes Rev. 5: 167-170. (Pubitemid 38998241)
29. Wirshing DA (2004). Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 65: 13-26.
30. Wirshing DA, Loyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC (2002). The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 63: 856-865. (Pubitemid 35231725)
31. th ed. Geneva: WHO.
32. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, et al (2006). Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology. 186: 572-578.